ACST News and Press, Acasti Pharma Inc. From 08/02/22

Call to be held on Thursday, August 11th at 1:00 PM Eastern Time LAVAL, Quebec, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), today announced that it will host a conference call at 1:00 ...

LAVAL, Quebec, July 27, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the relative bioavailability of GTX-101 c...

Phoenix, Arizona--(Newsfile Corp. - July 7, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and novel drug candidates addressing rare and orphan diseases. CEO of the Company, Jan D'Alvise, join...

LAVAL, Québec, June 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today a...

Acasti Pharma, Inc. (ACST) Q4 2022 Earnings Conference Call June 21, 2022 1:00 PM ET Company Participants Robert Blum - Investor Relations Jan D'Alvise - President and Chief Executive Officer Brian Ford - Chief Financial Officer Monique Champagne - Vice President, Clinical Affairs Conference ...

Acasti Pharma press release (NASDAQ:ACST): FY GAAP EPS of $0.27. Cash, cash equivalents and short-term investments totaled $43.7M as of March 31, 2022 vs. $60.7M in cash, cash equivalents and short-term investments as of March 31, 2021. Based on management’s current projections, curren...

Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, June 21, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capabil...

LAVAL, Quebec, June 16, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), today announced that it will host a conference call at 1:00 PM Eastern Time on Tuesday, June 21, 2022, to discuss the Company’s ...

Acasti Pharma (NASDAQ:ACST) said it received three composition of matter patents for brain hemorrhage therapy GTX-104 from the U.S. Patent and Trademark Office, the Japanese Patent Office, and the Australian Patent Office. In addition, one new patent for GTX-104 was awarded by the Indian...

LAVAL, Québec, June 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that three composition of matter patents for GTX-104 were issued by The United States Patent and Trademark Office,...